Drug intelligence / Profile preview

ABK-CDK-1

Development stage: Preclinical
Lead developer: Abbisko Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**ABK-CDK-1** is a novel, selective, brain-penetrant small molecule inhibitor of cyclin-dependent kinases 4 and 2 (CDK4/2) developed by Abbisko Therapeutics. It demonstrates superior potency in palbociclib-resistant models, good selectivity over CDK6, robust anti-tumor efficacy, and favorable drug-like properties, addressing limitations of existing CDK4/6 inhibitors, particularly for breast cancer patients with brain metastases or resistance.[2][4][7][10]

Targets

CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on ABK-CDK-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABK-CDK-1.

Explore the full profile